EVALUATION OF IL-6 AND IL-8 IN CANCER BREAST PATIENTS AND CORRELATION WITH TNM STAGING

Abstract

Introduction: Breast cancer is a global health concern, with one in eight women dying by age 90. Management involves age, menopausal status, tumor size, and estrogen levels. Estrogen and Progesterone receptor status are crucial for optimal prognosis. IL-6 and IL-8 concentrations could serve as biomarkers for disease progression and prognosis. Aims: This study aims to develop a feasible method for diagnosing and managing breast cancer, considering the strong association between elevated IL-6 and IL-8 serum concentrations. Methodology: The study analyzed data from breast cancer patients admitted to the Krishna Institute of Medical Sciences in Karad, focusing on their clinical stages, pre-operative evaluations, and inflammatory processes. Results: The study involved 70 participants aged 52.2 years and found that 40.0% had lesions in the Upper Outer Quadrant. The majority (62.9%) had T2 stage lesions. The study also showed a strong correlation between interleukin-6 and IL-8 levels with different T stages of a disease, with the highest levels observed in the N2 stage. Discussion: The study reveals elevated serum IL-6 and IL-8 levels in breast cancer patients, particularly advanced-stage cases, and a significant association with metastasis, potentially aiding in clinical management. Conclusion: The study explores the role of interleukin-6 and IL-8 levels in breast cancer patients, revealing their association with tumor, node, and metastasis staging, suggesting potential biomarkers.